-
National Medical Insurance Administration: 69 pharmaceutical companies have dishonesty behavior
Time of Update: 2021-11-03
What are the precautions that need to be taken?After the implementation of credit evaluation work, more and more pharmaceutical companies have realized the harmfulness of "rebates" and other behaviors, and have also taken active measures to correct their behaviors.
-
Qilu this year's 10 products to grab the first imitation new products aiming at $ 2 billion anti-tumor drugs
Time of Update: 2021-11-03
Figure 1: Qilu's Nilotinib Capsule Application Status Source: CDE official website Figure 2: Sales of Novartis's Nilotinib in the domestic market (unit: ten thousand yuan) Source: Mi Nei Net Database Novartis' nilotinib was approved to enter the domestic market in July 2009, and is currently in the 2020 edition of the National Medical Insurance Negotiation Catalog .
-
Pfizer/BioNTech Announces Phase 3 Clinical Data of mRNA Vaccine: Strengthen Needle to Show High Effectiveness!
Time of Update: 2021-11-03
Recently, Pfizer and BioNTech jointly announced the results of a phase 3 randomized controlled trial of COVID-19 mRNA vaccine Comirnaty (BNT162b2), which evaluated the 30μg booster dose of Comirnaty in more than 10,000 subjects 16 years and older Effectiveness and safety .
-
Crossing WHO-PQ certification domestically produced new crown vaccine to ensure vaccine supply in developing countries
Time of Update: 2021-11-03
Up to now, only the two vaccine manufacturers of China National Pharmaceutical Group Beijing Institute and Beijing Kexing Zhongwei have passed the WHO-PQ certification for the new crown vaccine, and the products are exported to overseas developing countries .
-
49 new drugs have been approved for clinical use!
Time of Update: 2021-11-03
OB756 piece Huadong Medicine/Hangzhou Bangshun Pharmaceutical has developed a class 1 new drug, OB756 tablets, for new indications and has been approved for clinical use.
The clinical application of the recombinant humanized anti-CD47 monoclonal antibody injection of Shandong New Times Pharmaceutical of Lunan Pharmaceutical Group was approved by NMPA.
-
"China Digital Therapy White Paper 2.0": Discover the key success factors in the whole process from R&D to business
Time of Update: 2021-11-03
When the wind lightly borrows its strength, it enters the sky in one fell swoop In May this year, eggshell Institute of Rehabilitation technology transfer and joint development of China Council for the Promotion of digital therapy System Engineering Committee (chips), far Yi capital jointly issued the first edition of "China Digital therapy industry White Paper", made from the connection to intervention Theme .
-
[In-depth analysis] Seeing the license-in/out variety selection strategy from the epidemiological differences between China and the United States
Time of Update: 2021-11-03
This has led to huge differences in the value of the same drugs in the domestic and foreign markets, which provides a market space for excess profits for Licensein/out projects .
-
Pfizer, Roche, and Huizhi's structural changes attract attention!
Time of Update: 2021-11-03
Pfizer China replicates the global structurePfizer China replicates the global structure There are three main points of China's organizational reform announced by Pfizer this time: First, six independent business units were established, namely hospital emergency, tumor, rare diseases, inflammation and immunity, vaccines, and broad markets .
-
18 new varieties passed the consistency evaluation, with 2 being the first (list attached)
Time of Update: 2021-11-03
In China, the original research emtricitabine propofol tenofovir was approved by the NMPA in December 2018 to be used in combination with other antiretroviral drugs to treat adults and adolescents (aged 12 years and older and weighing at least 35kg) HIV-1 infection, the trade name is Da Kehui .
-
86 drugs will be "kicked out" of medical insurance!
Time of Update: 2021-11-03
This week, the State Food and Drug Administration released two batches of reference preparation catalogs, and 69 pharmaceutical companies had dishonesty behavior; the market changed drastically, 86 medicines were "kicked out" from medical insurance, and 221 medicines were included in Guangdong's "dual channel" catalog.
-
Roche is again "first" today!
Time of Update: 2021-11-01
com/news/home/20210808005031/en/Phase-III-Study-Shows-Genentechs-Polivy-Plus-R-CHP-Is-the-First-Regimen-in-20-Years-to-Significantly-Improve- Outcomes-in-Previously-Untreated-Aggressive-Form-of-Lymphoma-Compared-to-Standard-of-Care [4] FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD).
-
PCT patent applications related to glucagon-like peptides and market analysis of GLP-1R agonists
Time of Update: 2021-11-01
The annual sales of GLP-1R receptor agonist antidiabetic drugs that have been marketed are shown in Figure 1 .
The previous analysis of GLP-related PCT patent applications found that all major GLP-related technologies are currently in the mature or growth stage, at least not in the decline period .
-
3 major development directions of mRNA in the future
Time of Update: 2021-11-01
Taking into account the target population penetration rate, pricing and competition in the main indications, it is estimated that the average peak sales value of each research and development pipeline project of the global preventive mRNA vaccine is about 800 million US dollars (for products other than the new coronary pneumonia vaccine).
-
Focus on drug targets: PD-1 / PD-L1, when will the internal volume be closed?
Time of Update: 2021-11-01
Its approval is based on a key global Phase III clinical study called CheckMate-649, which aims to evaluate its combined chemotherapy versus chemotherapy alone for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma as the first-line treatment Efficacy and safety in the global population (including Chinese patients) .
-
Zejing Pharmaceutical declares PD-1/TIGIT double antibody
Time of Update: 2021-11-01
On October 24, Zejing Pharmaceutical issued an announcement stating that its clinical trial application for ZG005 powder injection was accepted by the China Food and Drug Administration for the treatment of solid tumors .
-
How will the vaccine be interpreted in the second half of the "anti-epidemic war" that must be won?
Time of Update: 2021-11-01
S. FDA has successively approved three new EUA vaccine boosters, namely BioNTech/Pfizer’s COMIRNATY, Moderna’s mRNA-1273 and Johnson & Johnson’s adenovirus vector vaccine .
(3) Johnson & Johnson 's new crown vaccine booster was approved by the EUA on October 20 .
-
Analysis of National Drug Purchase Contract Renewal: Classified and Implementing Policies to Stabilize the Market and Encourage Innovation
Time of Update: 2021-11-01
At present, the renewal methods of nationally sourced varieties are still different in different regions: Hubei Province adopts the method of "inquiry before bidding", inquiring whether there is any new review status, and introducing unselected original research drugs at the original selected price.
-
Inventory of the hot areas of domestic substitution of medical devices, which industries are already gaining momentum?
Time of Update: 2021-11-01
In the past, basic medical device products that mainly relied on imports have basically achieved localization, and domestic substitution has gradually moved from the low-end market.
-
Genetron Health and Fosun Pharma reached an exclusive commercial cooperation on Seq-MRD®
Time of Update: 2021-11-01
According to the agreement, Genetron Health and Jiangsu Fosun Pharma will jointly sell and jointly promote Seq-MRD® in key hospitals and clinics for hematological diseases in designated areas in China to serve acute lymphoblastic leukemia, multiple myeloma, and chronic lymphocytic leukemia Waiting for patients with lymphatic hematological tumors .
-
The product pipeline is exciting!
Time of Update: 2021-10-22
Lung cancer field Source: Zai Lab Online R&D Day presentation In addition, he also discussed the unmet needs in the field of gastrointestinal tumors in China , and introduced related product pipelines, including bemarituzumab, margetuximab, TPX-0022, QINLOCK (repatinib), adagrasib and tumor electric field therapy .
